

The efficacy and safety of sarilumab, fully human monoclonal antibody targeting interleukin 6 receptor, in rheumatoid arthritis: new evidence

Nauchno-Prakticheskaya Revmatologiya

57, 564-577

DOI: 10.14412/1995-4484-2019-564-57

Citation Report

| # | ARTICLE | IF | CITATIONS |
|---|---|-----|-----------|
| 1 | The effect of olokizumab on rheumatoid arthritis patientâ€™s reported outcomes: results of a double-blind randomized placebo-controlled multicenter phase III trial (CREDO 1). Nauchno-Prakticheskaya Revmatologiya, 2021, 59, 62-69. | 0.2 | 5 |
| 2 | IMMUNOPATHOLOGY AND IMMUNOPHARMACOTHERAPY OF CORONAVIRUS DISEASE 2019 (COVID-19): FOCUS ON INTERLEUKIN 6. Nauchno-Prakticheskaya Revmatologiya, 2020, 58, 245-261. | 0.2 | 16 |
| 3 | Coronavirus disease-2019 (COVID-19): value of IL-6 inhibitors. Pulmonologiya, 2020, 30, 629-644. | 0.2 | 7 |
| 4 | Advances in rheumatology at the beginning of the 21st century. Nauchno-Prakticheskaya Revmatologiya, 2022, 60, 5-20. | 0.2 | 2 |
| 5 | Comparison of the efficacy and safety of the original rituximab and its biosimilar in routine clinical practice. Sovremennaya Revmatologiya, 2022, 16, 21-28. | 0.1 | 0 |
| 6 | Dynamics of patient reported outcomes during the use various biological disease-modifying antirheumatic drugs for rheumatoid arthritis. Nauchno-Prakticheskaya Revmatologiya, 2022, 60, 427-437. | 0.2 | 5 |
| 7 | The prospects of interleukin-6 inhibition in rheumatoid arthritis: Olokizumab (novel monoclonal) Tj ETQq0 0 0 rgBT /Overlock_10 Tf 50 5 | 0.2 | 6 |
| 8 | Secondary amyloidosis as a complication of rheumatoid arthritis in a patient with low adherence to treatment. Clinical Medicine and Pharmacology, 2023, 8, 35-40. | 0.1 | 0 |